As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literature searches for studies examining outcomes of watchful waiting and examined new literature emerging about the use of PSA for the follow-up of watchful waiting patients. Watchful waiting has the potential to play an increasingly important role in prostate cancer as less advanced disease is detected and methods are refined for identifying low-risk patients.
Introduction
Prostate cancer is the most common cancer in men. Autopsy studies show that by age 30-39, approximately 29% of men have microscopic evidence of disease, which increases to approximately 65% by age 70. 1 Fortunately, the proportion at risk of dying is low with approximately 29 000 deaths expected in 2005 in the United States (US). An ongoing debate surrounds the optimal treatment for men diagnosed with prostate cancer. Do they all need aggressive treatment or can many of them be treated by expectant management? Based on the high prevalence and low mortality, conservative therapy would appear to be a very reasonable option for a large proportion of men. This article examines the controversy and provides some evolving strategies for managing men conservatively.
Several terms have been used to describe noncurative therapy including 'watchful waiting', 'conservative therapy' and 'delayed therapy'. Traditionally, they all meant not administering local treatment. Instead, patients were monitored, usually by physical examination and bone scan, and if or when the disease progressed, the patients were treated by hormone therapy. The justification for this approach was that no study had ever demonstrated a better survival with local therapy and that local therapy often severely compromised quality of life.
One major change over the last 20 years is the development of an assay for prostate-specific antigen (PSA). This test has identified men whose prostate cancer was progressing before metastases occurred. As a result, local therapy could be offered when a tumor was still likely to be responsive. Hence, the most accurate term for those cases would now be delayed or expectant therapy.
Natural history of prostate cancer
Several studies have examined the role of watchful waiting prior to the widespread use of PSA. Perhaps the best data available was provided by Albertsen et al., 2, 3 who analyzed the results of men in Connecticut diagnosed with localized prostate cancer between 1971 and 1984. The importance of this study is that outcomes were stratified by Gleason score with Dr Gleason reviewing the biopsy material. At 15 years follow-up, they found the chances of dying from prostate cancer was 4-7% for Gleason 2-4 cancers, 6-11% for Gleason 5, 18-30% for Gleason 6, 42-70% for Gleason 7, and 60-87% for Gleason 8-10 (Table 1 ). This study is the only one to compare the survival for Gleason 5, 6 and 7 tumors separately. The authors found that survival for Gleason 5 cancer is significantly different than Gleason 6, which is also significantly different than Gleason 7 cancer.
These findings have important implications for all studies of therapy that attempt to make comparisons, since almost all report their results by combining Gleason 5, 6 and 7 together. Clearly such comparisons are invalid unless the distribution of Gleason 5, 6 and 7 tumors are similar in each cohort.
Recently, the authors reported a 20-year update of these data. 4 They found that few men with low-grade tumors had progression leading to death and most men with high-grade tumors died from prostate cancer regardless of their age at diagnosis (Table 1) .
Since Albertsen collected his data, two distinct changes have occurred in the pathologic findings of newly diagnosed prostate cancer. Currently, Gleason 2-4 is rare and Gleason 5 only slightly more common. Approximately 60-70% of all new cases diagnosed in the US now are Gleason 6 and 7 cancers. Whether this represents a true change in the disease or a changing approach to assigning Gleason scores is not clear. The second difference is that many men diagnosed today as a consequence of PSA testing have much smaller volumes of cancer on their biopsy than was observed by Albertson. It is highly likely that the natural history of these tumors is much more favorable than many of the cancers diagnosed before PSA was routinely used.
Another long-term population study [5] [6] [7] [8] described the natural history of prostate cancer in Swedish men over the course of 15 years ( Table 1 ). The corrected 15-yearsurvival was similar in the group who received deferred treatment (223 patients) and those who received immediate treatment (77 patients). The disease specific mortality for all tumor grades of those who received deferred therapy was 6.2, 13.2 and 19% at 5, 10 and 15 years, respectively. One potential problem with this study is that many of these men were diagnosed following transurethral resection of the prostate (TURP), which resulted in detecting many less aggressive tumors. Rates of death at 15 years from prostate cancer as either an underlying or contributory cause were 35/212 (16%) for highly differentiated cancers, 116/306 (38%) for moderately differentiated cancers and 84/124 (68%) for poorly differentiated cancers.
After a further 5-year follow-up, the disease-specific mortality for all grades increased to 45.6%. The prostate cancer mortality rate increased from 15/1000 person years during first 15 years to 44/1000 person years beyond 15 years. This population study portrays a good outlook for less aggressive therapy in patients with localized prostate cancer with a less than 15 years life expectancy. However, it questions the use of less aggressive management in those with a greater than 15 year life expectancy. Nevertheless, most of the tumors currently being diagnosed are smaller and of lower stage than those in this study meaning that many tumors diagnosed today have an even longer time before becoming life threatening.
Why the large discrepancy between cancer mortality rates for those still alive at 15 years between Albertsen's and Johansson's studies? One possible explanation may be that the tumors were classified using different methodology: by Gleason score in Albertsen's study and by the WHO classification by Johansson. These classifications have never been directly compared but in the WHO classification, grade 2 tumors could be either a Gleason score 5, 6 or 7. If a large proportion of the grade 2 tumors in Johansson's study were Gleason 7, the higher mortality rate in his study compared to the Albertsen report could be readily explained.
Another report of conservative therapy by Chodak et al. 9 also found a relatively low mortality in lower grade tumors. They performed a pooled analysis from six nonrandomized studies conducted in four countries including the Johansson data. Outcomes were reported for 828 patients with localized cancer, who did not undergo radical surgery or irradiation. A Cox regression analysis revealed grade 3 disease and age o61 years at diagnosis had a significant effect on disease specific survival. Disease-specific mortality at 10 years was 13% for grade 1 (Gleason 2-4) or 2 (Gleason 5-7) tumors but Table 1 Comparison of disease specific mortality
Gleason Grade
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Radical management of localized prostate cancer
The above studies provide reasonable estimates of longterm survival results when no definitive treatment is administered. However, to understand the relative impact of this approach on survival, a comparison with aggressively managed prostate cancer is needed. Gerber et al. 10 performed a large pooled analysis involving 2758 men with stage T1 or T2 disease who underwent radical prostatectomy at eight university institutions in the US and Europe. Disease-specific mortality at 10 years following surgery was 6% (range 2-13%) for grade 1 (Gleason 2-4), 20% (15-26% range) for grade 2 (Gleason 5-7) and 23% (14-35% range) for grade 3 (Gleason 8-10) tumors. These findings suggest little difference in survival for low-grade tumors and a very large difference for high-grade tumors when compared to the watchful waiting data. Of course, a comparison with the moderately differentiated cancers is not possible.
Recently, the only prospective, multicenter randomized trial involving 695 men was reported in which conservative management was compared to radical prostatectomy and results were analyzed according to the intention to treat.
11 At 6.2 years median follow-up, 31/348 (8.9%) of the watchful waiting group had died from prostate cancer compared with 16/347 (4.6%) of the radical prostatectomy group (P ¼ 0.02). in all, 15% of patients in the watchful waiting group had developed distant metastases compared to 10% in the radically treated group (P ¼ 0.03). Despite a small but significant difference in cancer-specific survival and metastatic rates, overall mortality was not significantly different (18% in the watchful waiting group compared to 15% in the radical prostatectomy group (P ¼ 0.31)).
More recently, Bill-Axelson et al. 12 reported the 10-year survival results from this study. The disease-specific mortality now is significantly higher in the watchful waiting group 50/348 (14.4%) compared to 30/347 (8.6%) in the radical prostatectomy group (P ¼ 0.01). The reduction in disease-specific mortality as a result of radical prostatectomy was greatest among patients younger than 65 years. The overall mortality was higher in the group assigned to watchful waiting; 30% compared to 24% (P ¼ 0.04). In all, 23% (79/348) of the watchful waiting group had progressed to metastatic disease compared to only 14% (50/347) in the radical prostatectomy group (P ¼ 0.004).
In addition, the difference in local progression (palpable transcapsular tumor growth) was statistically significant at both first and second follow-up in favor of radical prostatectomy: 18 versus 43% (Po0.001). In terms of quality of life, patients, who underwent a radical prostatectomy were less frequently administered hormones (110/347 compared to 177/348).
At 10 years, they concluded that radical prostatectomy was associated with a statistically significant reduction in all end points: absolute risk reduction of 5.3% in disease specific mortality, 10.2% in distant metastases, 25% in local progression and 5% in overall mortality. This is the first definitive evidence of a survival benefit for radical prostatectomy compared to conservative treatment. However, two problems could have biased the results toward the surgery arm: the watchful waiting group had more men with T1b disease (50 versus 33) and Gleason scores 7-10 (103 versus 91). Part of the small difference seen in mortality might be due to this imbalance.
Another critical aspect of this study that has implications for men diagnosed in the US is that the mean PSA at randomization was 12.9 ng/ml. If a similar study were performed in the US, a smaller difference in survival would most likely occur at 10 years due to the lower PSA level at diagnosis where the average is closer to 6 ng/ml. In other words, the overall survival benefit at 10 years from aggressive treatment may well be even lower than the 5% seen in this trial. Another randomized study, the PIVOT trial 13 is currently in progress and may validate the results from the Scandinavian study.
Current issues
Optimum management of clinically localized prostate cancer involves providing patients with accurate information about the impact on survival and quality of life with each therapy so that each man can weigh the options and participate in the choice about his treatment. For some men, their quality of life is more important than how long they live while in others the opposite is true. Each man must decide whether he would rather accept the risks from treatment to possibly avoid harm from his cancer in the future or face the slightly higher probability of suffering from his cancer in the future in order to maximize his quality of life.
Although age is a strong consideration, in this era of longer life expectancy, it is inappropriate to determine specific age cutoffs for one treatment over another. However, the decision to manage a patient with watchful waiting is made simpler in a patient with a reduced life expectancy, regardless of age. These patients are less likely to die of prostate cancer except for those with the highest-grade cancers. Expectant management appears to be a very sensible option for patients with clinically localized prostate cancer and life expectancy of o15 years especially with Gleason 2-5 cancer and for many men with a Gleason score of 6. Prior to the PSA era, Albertsen reported that there was no loss of life expectancy for men with Gleason 2-4 disease, while it was 4-5 years for Gleason 5-7 cancers and 6-8 years for Gleason 8-10 cancers. Those numbers are also highly likely to be lower in men diagnosed today by PSA.
Ideally, a clinician would be able to predict the biological behavior of a newly diagnosed cancer based on both patient and tumor characteristics and in doing so, help each patient decide on treatment which avoids over treatment of slow growing tumors and under treatment of aggressive ones. At present, making a reliable prediction is not possible. Currently, the single best predictor remains the Gleason score but the amount of cancer seen on biopsy may become increasingly useful in identifying low-risk disease. The best model for predicting insignificant tumor is PSA density o0.1 ng/ml/g with no adverse pathological findings on biopsy (no Gleason 4 cells) or PSA density 0.1-0.15 ng/ml/g with o3 mm low to intermediate grade cancer on only 1 needle biopsy core. This model has a positive predictive value of 95%. 14 
The future of active surveillance
Since the advent of PSA as a detection and monitoring tool, management of prostate cancer has changed dramatically. Disease progression can now be diagnosed much earlier well before metastases are present. Consequently, watchful waiting has evolved into active surveillance with many clinicians using changes in the PSA or PSA velocity to determine when a repeat biopsy or definitive therapy is indicated instead of just waiting for metastases to manifest.
In an attempt to definitively guide clinicians in managing watchful waiting patients, Klotz 15, 16 examined the use of PSA doubling time as a marker of when to initiate treatment. A prospective study of 299 patients found a disease specific survival at 8 years was 99% taking the approach of offering intervention to those patients with a PSA doubling time of o2 years or an increase in grade progression on rebiopsy. The majority of patients did not require intervention and the more likely appropriate threshold for PSA doubling time is likely to be about 3 years. 17 Active surveillance with selected delayed intervention based on PSA doubling time may provide a reasonable compromise between immediate local therapy, which results in over treatment of men with indolent disease, and prolonged watchful waiting, which results in under treatment of men with potentially progressive disease. This study is ongoing and does not yet provide any definitive guidance for men with a life expectancy of more than 10 years.
Another approach for identifying insignificant tumors is the use of saturation biopsies. A study used the criteria of no core with more than 50% involvement, Gleason score o7, fewer than 3 cores containing malignant cells and a PSA density of o0.15 as a predictor of insignificant tumor. In 103 men, 88.5% had insignificant tumor (organ confined, no Gleason 4 or 5 pattern and tumor volume o0.5 cm 3 ) on radical prostatectomy specimen. Although these criteria appear to be associated with low cancer volume, a prospective analysis of survival and disease progression in a cohort of these men is needed before it can be recommended.
Other studies have attempted to identify characteristics that are associated with progression of disease requiring active treatment. Younger patients are more likely to receive secondary treatment compared to older patients. [19] [20] [21] [22] Higher baseline and follow-up PSA level, Gleason score, percentage of positive biopsies, PSA doubling time and tumor stage are associated with increased probability of progression to active treatment and are significant independent predictors of intervention after initial management with watchful waiting. [20] [21] [22] Meng's study showed that out of 457 men managed initially with watchful waiting, freedom from treatment was 74% at 2 years, 63% at 3 years and 49% at 5 years. 20 When this figure is applied to the very large population of men with prostate cancer, it is clear that the number of patients who might avoid treatment could be enormous which has not only a quality of life benefit but also can reduce health care costs.
For the time being, patients looking to avoid immediate local therapy need to be counseled very carefully. These men need to be told that there is no guarantee that delaying therapy will result in the same chance for cure as immediate treatment following diagnosis. Nevertheless, it is also apparent that smaller, less advanced cancers are being increasingly diagnosed and clearly many of these men are unlikely to ever suffer from their disease even without local therapy. Although refinements are likely to occur over the ensuing years, one approach may be to select men using the Hopkins criteria and repeat PSA levels every 3-6 months and repeat biopsies every 12-24 months. Increase in tumor grade or tumor volume on biopsy or sequential increases in PSA may warrant a change in management but this could permit a large proportion of these men to avoid local therapy entirely. Hopefully, clinical studies will be forthcoming that provide outcome data from such an approach.
Conclusions
Based on historical data, many men diagnosed before PSA had a low risk of dying from their disease. Now with PSA diagnosing even more men with non-life threatening disease, there is a potential for middle ground between immediate aggressive therapy and delayed hormone therapy following metastases. This may enable many men with non-life threatening cancers to avoid unnecessary therapy without significantly compromising the outcome of the men who need and will benefit from definitive therapy. Hopefully, continued investigation in the area will help refine this approach.
